Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS) (NCT04581811), a randomized na study. The primary outcome is Duration in Prone Position.

2. Clinical Question

3. Trial Design

The registry identifies this as a randomized, parallel-arm pilot study with no masking. The study title specifies COVID-19-induced ARDS, and the registry lists ARDS, COVID-19, and acute hypoxemic respiratory failure as conditions. Enrollment was 52. The posted primary outcome has 26 participants in each arm.

The prolonged arm was described as receiving 24 hours in the prone position followed by 8 hours in the supine position for the duration of the study. The traditional arm was described as receiving standard 16-hour prone positioning followed by 8 hours supine for the duration of the study. The primary outcome timeframe was 96 hours. The registry lists the study as completed, with a start date of 2020-11-10 and a primary completion date of 2021-03-20.

The official title calls the study a pilot. Its listed phase is NA. The registry does not report further details about the randomization procedure, allocation concealment, eligibility criteria, or how adherence to the assigned positioning schedules was assessed. The registry record also does not report the study's original sample-size justification or the statistical plan used by investigators. Those omissions limit what can be concluded about the trial's design choices and planned analyses; they do not alter the reported arm-level outcome summaries.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Duration in Prone Position, measured over 96 hours.

The primary endpoint is titled Duration in Prone Position. It is a continuous measure reported as the mean number of hours spent prone during the 96-hour timeframe. The description specifies time spent in the prone position among hours eligible for prone positioning. The registry reports a mean and standard deviation for each arm.

This endpoint directly addresses whether the positioning schedules resulted in different amounts of time spent prone. That makes it relevant to comparing the two assigned schedules as delivered over the study timeframe. It is distinct from outcomes such as oxygenation, ventilator-free days, or mortality: a difference in positioning duration alone does not establish a difference in those clinical outcomes.

Means describe the central value of a continuous outcome across participants, while standard deviations describe how spread out participant values are around the mean. A mean can summarize the group, but it does not show each participant's experience or the shape of the distribution. The registry's description also ties the measure to hours eligible for prone positioning; further details about eligibility for those hours, missing observations, and the calculation of each participant's duration are not reported in the registry record.

7. Results Posted in the Registry

• Traditional Proning Arm: mean 45.70 versus 56.60 on control; difference -10.90 (95% CI -22.15 to 0.35), standardized effect d = -0.53; z-test p = 0.058.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Change in P:F Ratio

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Traditional Proning Arm: mean 44.30 versus 46.60 on control; difference -2.30 (95% CI -31.19 to 26.59), standardized effect d = -0.04; z-test p = 0.876.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Traditional Proning Arm and the control. The interval gives the range of effects that remain compatible with the data.

Change in Drive Pressure

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Traditional Proning Arm: mean 0.88 versus 0.16 on control; difference 0.72 (95% CI -1.56 to 3.00), standardized effect d = 0.17; z-test p = 0.536.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Traditional Proning Arm and the control. The interval gives the range of effects that remain compatible with the data.

Pressure Ulcers

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Traditional Proning Arm: 0.0% (0/26) versus 3.8% (1/26) on control; risk difference -3.8 percentage points (95% CI -11.2 to 3.5); unadjusted two-proportion z-test p = 0.313.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Traditional Proning Arm and the control. The interval gives the range of effects that remain compatible with the data.

The registry lists 11 posted secondary outcomes, spanning respiratory measurements, events, and clinical outcomes. The available numeric summaries cover only some of these measures. The posted secondary comparisons include mean differences for change in P:F ratio and drive pressure, and a risk difference for pressure ulcers. The remaining outcomes are listed in the registry, but their results are not reported in the registry record.

These outcomes provide context for the primary endpoint but address different questions. The primary result concerns duration in prone position; respiratory measurements reflect different aspects of physiology, while event and clinical outcomes have their own definitions and timeframes. A pattern across these measures could be informative, but it cannot be treated as a single confirmatory test when endpoints differ in meaning and measurement. The secondary outcomes also do not change what the primary endpoint measures.

The posted secondary comparisons are unadjusted, and the registry does not report a multiplicity plan. When many outcomes are examined, the chance of finding an apparently unusual result somewhere among them can increase, even if there is no real underlying effect. This general concern means that isolated secondary p-values should carry less weight than results from a clearly prespecified primary analysis. It also means that a lack of an apparently unusual secondary result is not proof of no effect, particularly where estimates are imprecise.

The registry record does not report a complete analysis plan, and it lists 0 reported analyses for the primary outcome. No specific hierarchy, correction procedure, or confirmatory status for the secondary outcomes is documented. Accordingly, secondary findings are best viewed as exploratory context rather than independent confirmation of the primary comparison. Their interpretation should account for their distinct outcome definitions, the small arm sizes, and the possibility of chance variation across multiple measures.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Change in P:F Ratio
• Change in Drive Pressure
• Unplanned Extubations
• Pressure Ulcers
• Line Displacement
• Vent Free Days
• Mortality
• Rescue Interventions

9. Statistical Interpretation

10. Statistical Methods Explained

Several basic statistical ideas help interpret these results. The discussion below explains those ideas generally and distinguishes them from methods specifically documented in the registry record.

What does a mean difference represent?

For a continuous outcome, a mean difference compares the average values in two groups. In this trial's posted comparison, the traditional-positioning arm is contrasted with the prolonged-positioning arm. The estimate of -10.9 hours is therefore a signed contrast in that direction, rather than a separate mean for either group. The arm-level means, 45.7 and 56.6 hours, provide the group summaries from which the comparison can be understood.

The standard deviation describes variation among individual observations within an arm. It is not the same as the standard error, which describes uncertainty in an estimated mean. The registry reports standard deviations of 20.8 hours and 20.6 hours for the two arms. The group summaries do not reveal whether values were symmetric, skewed, clustered, or affected by extreme observations. Distributional details are not reported in the registry record.

What does a confidence interval communicate?

In general, a confidence interval represents uncertainty around an estimate under a particular statistical method and its assumptions. A narrower interval indicates greater precision; a wider interval indicates less precision. The primary comparison interval extends from -22.15 to 0.353 hours and includes zero. This means the posted estimate does not pin down a single direction of difference with high precision. The interval should be interpreted alongside the point estimate, endpoint definition, and trial context, rather than as a range of all possible individual outcomes.

A confidence interval is not a guarantee that the true value lies within its endpoints, nor is it a probability statement about the hypothesis. Its interpretation relies on the analysis method and assumptions. The registry record does not identify the investigators' interval-construction method. The posted comparison gives a point estimate and interval, but the underlying analysis details are not reported.

What does an unadjusted p-value say?

Generally, a p-value measures how unusual the observed data, or data more extreme, would be under a specified null model and analysis assumptions. The primary comparison has an unadjusted p-value of 0.058. The word unadjusted matters: the value is not described as corrected for the number of outcomes or comparisons. It should not be interpreted as the probability that the null hypothesis is true or as a measure of clinical importance. The registry record does not report the investigators' prespecified significance threshold or complete analysis plan.

In general, a p-value and confidence interval answer related but different questions. The interval emphasizes plausible values and precision under the method, while the p-value summarizes compatibility with a null hypothesis under its model. Neither replaces consideration of study design, sample size, outcome relevance, and potential bias.

Why can variability affect precision?

General statistical principle: greater variability makes group means harder to estimate precisely when sample size is held constant. This is one reason standard deviations matter when interpreting continuous outcomes. In outcomes with counts or event rates, extra variability beyond what a simple model expects is often called over-dispersion. General explanation: over-dispersion can make standard errors too small if a model assumes less variation than the data contain, leading to confidence intervals that are too narrow and p-values that are too optimistic. The registry does not report an over-dispersion assessment or a model for the primary outcome, so no such property should be attributed to this trial.

What can be inferred from the reported analysis?

The registry lists 0 reported analyses for the primary outcome and no reported analyses for the posted secondary measures. It does post arm-level summaries and comparison estimates. The record does not describe whether comparisons were adjusted for baseline variables, how missing measurements were treated, whether all randomized participants were included, or whether the analysis followed assignment regardless of adherence. These are important distinctions in randomized trials. An intention-to-treat analysis, for example, generally retains participants in their randomized groups; that is a general concept, not an analysis method documented for this study.

The registry record also does not report a prespecified statistical analysis plan, the method used to generate the posted comparisons, or interim analyses. Without those details, the numerical summaries can be described as posted, but the analytical choices behind them cannot be fully evaluated. No adjustment or modeling method should be assumed beyond what the record states.

11. Confidence Intervals and Precision

Precision is central to interpreting the primary comparison. The mean difference is -10.9 hours, and its confidence interval runs from -22.15 to 0.353 hours. The interval includes zero and spans values consistent with a lower mean in the traditional arm as well as a value slightly in the opposite direction. Thus, the estimate does not precisely determine the direction or magnitude of the underlying difference.

The group standard deviations are 20.6 hours in the prolonged arm and 20.8 hours in the traditional arm. These describe participant-to-participant variation, not uncertainty in the mean difference itself. The interval incorporates sampling uncertainty in the comparison; its width reflects that the estimate is not highly precise. With 26 participants in each arm contributing to the posted primary summaries, the trial provides limited information for distinguishing among effects of different sizes.

Confidence intervals are useful because they show more than whether a test crosses a conventional threshold. They indicate the range of estimates compatible with the data and method, subject to assumptions. The upper endpoint is close to zero, but the interval should not be reduced to a binary judgment based on that boundary. Nor does inclusion of zero demonstrate that the schedules have identical effects. The interval allows uncertainty about both the size and direction of a difference.

The registry does not report the interval method, missing-data handling, or analysis population. Those omissions matter because precision depends on the analysis as well as the observed variability and sample size. The interval is therefore best read as the precision of the posted comparison, not as a complete account of all uncertainty or potential bias.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning figures are sample-size illustrations based on the observed primary effect, not the original trial design calculation. They give participants per arm, rather than total events. The stated assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. Each planning scenario uses the stated fraction of the observed effect as the effect to detect. The original study's own sample-size justification is not reported in the registry record.

The 80% power column gives the estimated participants per arm for a design that would have an 80% chance of detecting the specified effect under the planning assumptions, if that effect and assumptions were correct. The 90% power column uses a higher target chance of detection and therefore generally requires more participants per arm. These are design-planning concepts, not guarantees about a future study's result. The figures for the primary endpoint range from 57 participants per arm when planning for 100% of the observed effect to 227 participants per arm when planning for 50% of the observed effect at 80% power. For 90% power, the corresponding listed figures range from 76 to 304 participants per arm.

The rows planning for 75% and 50% of the observed effect illustrate an important general principle: smaller effects are harder to distinguish from random variation and require more participants to reach the same power target. The displayed planning results are illustrations using the posted effect estimate. They are not observed power, and they do not establish the sample size that the investigators originally intended or needed.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = -10.900; pooled standard deviation σ = 20.700.
2. n = 2 × (1.96 + 0.842)² × 20.700² / -10.900² = 56.6, rounded up to 57 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- -10.9                      # observed difference in means
sigma <- 20.7002415444845                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(4581811)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 57 (80% power), 76 (90% power)
 75% of observed effect: n per arm = 101 (80% power), 135 (90% power)
 50% of observed effect: n per arm = 227 (80% power), 304 (90% power)
power.t.test: 57.6 
Simulated power at n = 57 per arm: 0.794 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Multiplicity, Missing Data and Analysis Populations

The registry lists 12 outcome measures, including the primary endpoint and secondary outcomes, while 11 secondary outcomes are posted. The record does not report a multiplicity strategy describing how the chance of false-positive findings across multiple comparisons was handled. This matters because evaluating many outcomes can produce an apparently notable result by chance even when each comparison is considered separately. Unadjusted results should therefore be interpreted cautiously, especially for secondary outcomes that may be exploratory.

The registry lists 0 reported analyses for the primary outcome, and the secondary outcomes also have no reported analyses. Posted summaries and comparisons are available, but the record does not give a full statistical analysis plan, identify a prespecified testing hierarchy, or describe whether any secondary outcomes were designated as confirmatory. The investigators' intended treatment of multiplicity is not reported in the registry record.

Information about missing data and analysis populations is also absent. The registry record does not report the number of participants with missing measurements, reasons for missingness, imputation methods, or whether analyses included all randomized participants. It does not specify whether participants were analyzed according to randomized assignment or according to the positioning they received. These details can affect both the interpretation of group comparisons and the extent to which randomization is preserved in the analysis.

The absence of these details does not establish that data were missing or that analyses departed from a plan. It means the posted record does not allow those issues to be evaluated. Similarly, the registry does not report interim analyses or stopping rules. Conclusions should remain focused on the observed summaries and their uncertainty, without assuming an unreported analytical procedure.

15. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The adverse-event summaries report 26 participants at risk in each arm. For serious adverse events, 0 participants were affected in the prolonged arm and 0 in the traditional arm. The summaries also report 0 participants affected by other adverse events in each arm. These figures describe what is posted for the registry outcome and do not, by themselves, establish that no adverse events of any kind occurred outside the captured definitions or reporting period.

The registry separately reports 14 deaths in the prolonged arm and 15 in the traditional arm. Deaths are an important distinct outcome in these summaries; they should not be conflated with the count of participants affected by serious adverse events. The record does not provide event timing, causes, an analysis comparing mortality between arms, or detailed definitions and ascertainment procedures for these adverse-event summaries. Those details are not reported in the registry record.

Small group sizes and the absence of reported analytical detail limit what can be inferred from these safety figures. The numbers are descriptive counts, not evidence that one schedule is safer or less safe than the other.

16. What the Result Does, and Does Not, Mean

The posted primary result describes a difference in the amount of time participants spent prone under the two assigned schedules during the 96-hour timeframe. The prolonged arm's mean was 56.6 hours, compared with 45.7 hours in the traditional arm. The comparison estimate was -10.9 hours for traditional relative to prolonged, and its confidence interval included zero. These data describe the observed positioning durations and the uncertainty around their comparison.

The result does not show whether either schedule changes mortality, ventilator-free days, or other clinical outcomes. Those are separate outcomes, and the registry's primary endpoint is duration in prone position. Nor does the result establish that the observed difference in average duration is a reliable estimate of what would occur in another group of patients. The confidence interval is broad, the trial is a pilot, and each arm's posted primary summary includes 26 participants.

An interval that includes zero does not prove that the schedules are equivalent. It indicates that the data and posted method do not resolve the difference precisely. Conversely, the difference between the arm means should not be presented as proof of a clinical benefit. Statistical evidence about an endpoint and clinical importance are distinct questions; the registry record does not give a threshold for a clinically important difference in prone-position duration.

The secondary outcomes may provide additional context, but many are not accompanied by posted results, and the record does not describe a plan for multiple testing. Missing details about the analysis population, missing data, and statistical methods further limit interpretation. A careful reading therefore keeps the conclusion narrow: the posted means differ, while the comparative estimate remains uncertain and does not answer broader clinical questions.

17. Why This Trial Matters Statistically

This pilot trial is statistically interesting because its primary endpoint measures whether the assigned positioning schedules translated into different exposure to prone positioning. That is a direct process measure of the intervention, rather than a clinical outcome. Separating implementation from clinical consequences is important: a schedule may change exposure without necessarily changing other outcomes, and those questions require their own data and analyses.

The comparison also illustrates why estimates need to be read with their uncertainty. The observed arm means are distinct, but the confidence interval around the mean difference includes zero. The point estimate alone therefore tells an incomplete story. Looking at the interval makes clear that the direction and size of the difference are not determined precisely by the posted data.

The sample-size illustrations show how planning depends on the effect a future study aims to detect. A study designed around a smaller effect requires more participants per arm than one designed around the full observed effect, under the stated assumptions. Because the observed effect itself is uncertain, planning from it is only illustrative; it is not a substitute for a justified target effect or an original design rationale.

Finally, the registry record offers a useful example of the limits of outcome reporting. It lists numerous secondary measures, but not all have posted results, and it does not report multiplicity handling, missing-data methods, or a full analysis plan. These gaps shape how confidently the results can be interpreted. Statistical significance alone cannot resolve design and reporting uncertainty, and the clinical relevance of a process endpoint should not be confused with an outcome that directly measures how participants fare.

18. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations specific to this registry record affect interpretation. The study is titled a pilot and has 52 enrolled participants, with 26 participants in each arm represented in the posted primary summaries. The primary comparison is imprecise, so the estimate does not settle the direction or size of the difference. The registry's original sample-size justification is not reported, and the planning illustrations based on the observed effect should not be mistaken for the original design rationale.

The primary endpoint measures duration in prone position, not a clinical outcome. Its description refers to hours eligible for prone positioning, but the registry does not provide further operational details about eligibility, measurement, or missing observations. The record does not report the analysis population, missing-data methods, baseline adjustment, or the statistical model used for the primary comparison.

The trial was randomized and had no masking according to the registry. The record does not describe allocation concealment or how adherence to the positioning schedules was monitored. These details cannot be assumed. The record also does not report a complete statistical analysis plan, interim analyses, or a strategy for multiple outcomes. Although several secondary outcomes are listed, results are not posted for all of them.

Safety summaries provide counts, but the registry does not report detailed definitions, event timing, causes of death, or comparative analyses for those outcomes. Taken together, these limitations support a restrained interpretation centered on the posted descriptive results and their uncertainty. They do not establish that unreported methods were inadequate; they identify what cannot be evaluated from the registry record.

19. Related Tutorials

20. Related Statistical Calculators

21. Sources

• ClinicalTrials.gov: Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS) — NCT04581811.
• Registry record last updated 2022-03-31; status last verified 2022-03.
• Results first posted 2022-03-31.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

22. Record Summary

NCT04581811 is a completed, randomized, open-label, parallel-arm pilot study sponsored by the University of Alabama at Birmingham. It enrolled 52 participants with COVID-19-induced ARDS, comparing prolonged with traditional prone positioning. The primary endpoint was mean duration in prone position over 96 hours.

The posted primary summaries report means of 56.6 hours in the prolonged arm and 45.7 hours in the traditional arm. The traditional-versus-prolonged mean difference was -10.9 hours, with a confidence interval that includes zero. The registry lists 11 secondary outcomes, but not all have posted results. Details of the original sample-size justification, full analysis plan, missing-data handling, and multiplicity strategy are not reported in the registry record.